Serplulimab
Monoclonal antibody
Evidence outlook
Approved: First-line advanced squamous NSCLC with carboplatin and nab-paclitaxel (article dated... (EU)
This approval is outside the US-scoped market view; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.
track record: Reliable signal
Also in development:Small Cell Lung Cancer · Phase 3 · investigational in the USGastric Cancer · Phase 3 · investigational in the US
Also approved (7)
- First-line advanced squamous NSCLC with carboplatin and nab-paclitaxel (article dated 2026-06-25)
- First-line non-squamous NSCLC (no EGFR or ALK/ROS1 mutations) with carboplatin and pemetrexed; also metastatic oesophageal squamous cell carcinoma
- First-line extensive-stage small cell lung cancer with carboplatin and etoposide (Hetronifly)
- First-line extensive-stage small cell lung cancer with carboplatin and etoposide (Hetronifly)
- Adults with previously untreated extensive-stage small cell lung cancer (Hetronifly)
- First-line extensive-stage small cell lung cancer with carboplatin and etoposide
- First-line unresectable locally advanced or metastatic squamous NSCLC with carboplatin and nab-paclitaxel
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
SUPER BRAIN NCT05807893 · Non-small Cell Lung Cancer Stage II, Bevacizumab, Immunotherapy, Brain Metastases Study of the molecule, not a specific product The study treated 40 participants in a non-randomized, open-label, single-arm design without a comparator group. Its primary endpoint was intracranial progression-free survival. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Registry: NCT05807893 | 2/3 | iPFS (The time from receipt of study treatment to intracranial tumor PD or to death due to any cause,whichever came first, assessed up to 60 months) 2024-03-22 | Median intracranial PFS (iPFS): 13.1 months; 6-month iPFS rate 91.3%; 12-month iPFS rate 67.1% (serplulimab + bevacizumab + chemotherapy, first-line, non-squamous NSCLC with untreated brain metastases). | Weak signal | link ↗ |
View 2 more trials
NCT03952403 NCT03952403 · Carcinoma, Non-Small-Cell Lung Study of the molecule, not a specific product This is a large, randomized, quadruple-blind, placebo-controlled Phase 3 trial comparing serplulimab-plus-chemotherapy combinations against chemotherapy alone in advanced lung cancer, with progression-free survival as its main measure. The trial is well-designed. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. The first listed primary outcome for this study is Part 1 safety and tolerability; the survival figures shown here are the Part 2 primary endpoint (progression-free survival) and the overall-survival secondary endpoint from the final analysis. Registry: NCT03952403 | 3 | Part 1 Safety and tolerability of study treatment (baseline to 21 days); Part 2-Progression Free Survival (PFS) as Determined by the IRRC using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) (Baseline until disease progression or death, whichever occurs first (up to approximately 24months)) 2023-10-01 | Final analysis in nonsquamous NSCLC: median overall survival reached 26.8 months for Hetronifly (serplulimab) plus chemotherapy compared with 20.3 months for chemotherapy alone, a 34% reduction in the risk of death (HR=0.66, 95% CI: 0.52-0.83, P<0.001); median PFS was 11.0 months in Group B versus 5.7 months in the chemotherapy-only arm. No statistical difference was observed for Group A compared to Group B (HR=1.12, p=0.3628). | Partial signal | link ↗ |
NCT04033354 NCT04033354 · Squamous Non Small Cell Lung Cancer Study of the molecule, not a specific product In this randomized, double-blind, placebo-controlled Phase 3 trial of 537 patients with advanced squamous non-small-cell lung cancer, adding serplulimab to platinum-based chemotherapy significantly extended progression-free survival compared with chemotherapy plus placebo, and overall survival was also significantly improved at final analysis. Registry: NCT04033354 | 3 | tumor assessment (Baseline until disease progression or death, whichever occurs first (up to approximately 24months)) 2023-12-30 | At the final analysis, serplulimab plus chemotherapy significantly improved median OS compared to placebo plus chemotherapy (HR 0.73, 95% CI 0.58-0.93; p=0.010); at the second interim analysis, the PFS benefit was maintained in the serplulimab-chemotherapy group (HR 0.53, 95% CI 0.42-0.67). | Reliable signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
This page stands for the molecule. Studies that name only the molecule, and no branded product, are listed here and are marked as studies of the molecule. A study of a branded product is on that product's page.
Phase 3 (18)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (113)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (8)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (9)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (2)
What this study did
What this study did
Early phase / not applicable (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Appears in other studies (11)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 2 (9)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (2)
What this study did
What this study did
Competitive landscape
Other PD-1 drugs
Cemiplimab, Dostarlimab, Nivolumab, Opdivo Qvantig, Pembrolizumab and 21 more. Compare all 27 PD-1 drugs
This mechanism is crowded: 26 other tracked programmes target it, 10 of them ahead of this one.
This drug's own stage for Gastric Cancer: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Serplulimab: this drug | Phase 3 | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Capecitabine | ApprovedUS marketing discontinued | Small molecule | Fluoropyrimidine (antimetabolite) | not yet graded | No reviewed efficacy summary in this indication | |
| Docetaxel (Taxotere) | Approved | Small molecule | Microtubules (tubulin) | not yet graded | No reviewed efficacy summary in this indication | |
| Nivolumab | Approved | Monoclonal antibody | PD-1 | Partial signal | No reviewed efficacy summary in this indication | |
| Opdivo Qvantig | Approved | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Pembrolizumab | Approved | Monoclonal antibody | PD-1 | Reliable signal | No reviewed efficacy summary in this indication | |
| Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex) | Approved | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Ramucirumab | Approved | Monoclonal antibody | VEGFR2 | Reliable signal | NCT01170663: Overall Survival Time (OS) (Randomization up to 27.5 months): Ramucirumab (IMC-1211B) Plus Paclitaxel 9.6 months (95% CI 8.5 to 10.8) | Placebo Plus Paclitaxel 7.4 months (95% CI 6.3 to 8.4) NCT00917384: Overall Survival (OS) (Randomization up to 28 months post-randomization): IMC-1121B (Ramucirumab) 5.2 months (95% CI 4.4 to 5.7) | Placebo 3.8 months (95% CI 2.8 to 4.7) | |
| Tislelizumab | Approved | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Zanidatamab | Approved | Multispecific antibody | HER2 | not yet graded | No reviewed efficacy summary in this indication | |
| ASP2138 | Phase 3 | Multispecific antibody | Claudin 18.2 x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| Camrelizumab | Phase 3 | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Disitamab Vedotin | Phase 3 | Antibody–drug conjugate | HER2 | not yet graded | No reviewed efficacy summary in this indication | |
| Iparomlimab (QL1604) | Phase 3(overall) | Monoclonal antibody | PD-1 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| ONO-4578 | Phase 3 | Small molecule | Prostaglandin E2 receptor 4 (EP4) | Reliable signal | NCT06256328: ONO-4578-08 study (NCT06256328): median PFS 9.0 months (ONO-4578 + nivolumab + chemotherapy) vs 6.9 months (placebo + nivolumab + chemotherapy); HR 0.67, 90% CI 0.48-0.92, P=0.040. | |
| Retlirafusp Alfa | Phase 3 | Multispecific antibody | PD-L1 and TGF-beta (TGF-βRII trap) | Partial signal | NCT04950322: Primary endpoint, overall survival vs placebo plus CAPOX: median 16.8 vs 10.4 months (HR 0.53) in PD-L1 CPS >=5 and 15.8 vs 11.2 months (HR 0.66) in the ITT set (JCO, 2026-09-24). | |
| Rilvegostomig | Phase 3 | Multispecific antibody | PD-1 and TIGIT | not yet graded | No reviewed efficacy summary in this indication | |
| S-1 | Phase 3 | Small molecule | Thymidylate synthase (via 5-FU, released from tegafur) and dihydropyrimidine dehydrogenase (inhibited by gimeracil) | not yet graded | No reviewed efficacy summary in this indication | |
| Sonesitatug Vedotin | Phase 3 | Antibody–drug conjugate | Claudin 18.2 (CLDN18.2) | not yet graded | No reviewed efficacy summary in this indication | |
| Trastuzumab Rezetecan | Phase 3 | Antibody–drug conjugate | HER2 | not yet graded | No reviewed efficacy summary in this indication | |
| agenT-797 | Phase 2 | Cell therapy | Invariant TCR / NKG2D ligands (tumor cell recognition), no single defined myeloma antigen | not yet graded | No reviewed efficacy summary in this indication | |
| Givastomig | Phase 2 | Multispecific antibody | Claudin 18.2 (CLDN18.2) x 4-1BB | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-3045 | Phase 2(overall) | Undisclosed | PD-1 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| SHR-A1904 | Phase 2 | Antibody–drug conjugate | Claudin 18.2 (CLDN18.2) | not yet graded | No reviewed efficacy summary in this indication | |
| ASP546C | Phase 1/2(overall) | Antibody–drug conjugate | Claudin 18.2 (CLDN18.2) | not yet graded | No reviewed efficacy summary in this indication | |
| TAK-921 | Phase 1/2 | Antibody–drug conjugate | — | not yet graded | No reviewed efficacy summary in this indication | |
| Afivastobart | Phase 1 | Monoclonal antibody | CD39 (ENTPD1) | not yet graded | No reviewed efficacy summary in this indication | |
| Bmab1700 | Phase 1(overall) | Monoclonal antibody | PD-1 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| CRX100 | Phase 1 | Cell therapy | Cell-based oncolytic virus immunotherapy | not yet graded | No reviewed efficacy summary in this indication |
Compare side by side
17 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(80 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Serplulimab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.